12:05 PM EST, 03/05/2024 (MT Newswires) -- Vir Biotechnology ( VIR ) said Tuesday it completed enrollment of its current groups in a phase 2 clinical trial of tobevibart and elebsiran to treat chronic hepatitis delta virus one month earlier than projected.

The company said this includes more than 60 participants in two additional groups, with one evaluating tobevibart given every two weeks and the other evaluating the tobevibart and elebsiran combination given every four weeks.

Vir Biotechnology ( VIR ) expects initial data in Q2, while additional 24-week treatment data for all participants is expected in Q4, the company said.

Price: 11.25, Change: +0.06, Percent Change: +0.49